Prenetics Global (PRE) Registration Filing summary

Company overview and business model

• Focuses on global consumer health, longevity, and preventive wellness solutions, leveraging scientific expertise and digital asset innovation.

• Operates under a unified Consumer Health segment, with brands like IM8 Health (premium supplements) and CircleDNA (genetic testing).

• Holds a 35% stake in Insighta, an early cancer detection company, and has divested ACT Genomics to streamline operations.

• Strategic transformation includes a significant Bitcoin treasury strategy, integrating digital assets into the health ecosystem.

Financial performance and metrics

• IM8 Health achieved over $60 million annual recurring revenue (ARR) within six months of launch, targeting $100 million ARR by year-end.

• As of May 31, 2025, pro forma current assets were approximately $112 million, with $65 million in cash and equivalents, assuming ACT Genomics divestment and $20 million Bitcoin investment.

Use of proceeds and capital allocation

• Net proceeds from securities sales are intended primarily for Bitcoin acquisition and general corporate purposes, with management retaining broad discretion over allocation.

• Board-approved long-term strategy includes allocating most of the balance sheet to Bitcoin and implementing alpha-generating strategies.